Doug Altman: Driving critical appraisal and improvements in the quality of methodological and medical research
暂无分享,去创建一个
G. Collins | P. Royston | W. Sauerbrei | S. Evans | M. Schumacher | R. Riley | M. Bland
[1] S. Cessie,et al. Hidden analyses: a review of reporting practice and recommendations for more transparent reporting of initial data analyses , 2020, BMC Medical Research Methodology.
[2] M. Woodward,et al. Design choices for observational studies of the effect of exposure on disease incidence , 2019, BMJ Open.
[3] D. Rennie. A Tribute to Douglas G. Altman, DSc. , 2019, JAMA.
[4] Gary S. Collins,et al. Reporting of artificial intelligence prediction models , 2019, The Lancet.
[5] G. Collins,et al. Uniformity in measuring adherence to reporting guidelines: the example of TRIPOD for assessing completeness of reporting of prediction model studies , 2019, BMJ Open.
[6] Richard D Riley,et al. A guide to systematic review and meta-analysis of prognostic factor studies , 2019, British Medical Journal.
[7] Douglas G Altman,et al. Statistical methodology for constructing gestational age‐related charts using cross‐sectional and longitudinal data: The INTERGROWTH‐21st project as a case study , 2018, Statistics in medicine.
[8] R. Porcher,et al. Overinterpretation and misreporting of prognostic factor studies in oncology: a systematic review , 2018, British Journal of Cancer.
[9] D. Moher,et al. Doug Altman's legacy to Cochrane and evidence synthesis. , 2018, The Cochrane database of systematic reviews.
[10] G. Collins,et al. Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement , 2018, BMC Medicine.
[11] Maarten van Smeden,et al. Sample size for binary logistic prediction models: Beyond events per variable criteria , 2018, Statistical methods in medical research.
[12] G. Watts. Douglas Graham Altman , 2018, The Lancet.
[13] I. Chalmers,et al. Douglas G Altman: statistician, researcher, and driving force behind global initiatives to improve the reliability of health research , 2018, British medical journal.
[14] W. Sauerbrei,et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration , 2018, Journal of the National Cancer Institute.
[15] David Moher,et al. Flaws in the application and interpretation of statistical analyses in systematic reviews of therapeutic interventions were common: a cross-sectional analysis. , 2018, Journal of clinical epidemiology.
[16] D. Altman,et al. Population attributable fraction , 2018, British Medical Journal.
[17] D. Altman,et al. The INTERGROWTH‐21st fetal growth standards: toward the global integration of pregnancy and pediatric care , 2018, American journal of obstetrics and gynecology.
[18] Georg Heinze,et al. Variable selection – A review and recommendations for the practicing statistician , 2018, Biometrical journal. Biometrische Zeitschrift.
[19] S. Lewis,et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials , 2017, JAMA.
[20] Jane M Blazeby,et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations , 2017, PLoS medicine.
[21] Angus G K McNair,et al. The COMET Handbook: version 1.0 , 2017, Trials.
[22] W. Sauerbrei,et al. Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles , 2017, PloS one.
[23] L. Hooft,et al. A guide to systematic review and meta-analysis of prediction model performance , 2017, British Medical Journal.
[24] Douglas G. Altman,et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis , 2016, BMC Medical Research Methodology.
[25] Douglas G. Altman,et al. Adequate sample size for developing prediction models is not simply related to events per variable , 2016, Journal of clinical epidemiology.
[26] L. Watering. Faculty of 1000 evaluation for Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. , 2016 .
[27] David Moher,et al. A new classification of spin in systematic reviews and meta-analyses was developed and ranked according to the severity. , 2016, Journal of clinical epidemiology.
[28] S. Goodman,et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations , 2016, European Journal of Epidemiology.
[29] W. Sauerbrei,et al. Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example , 2016, PloS one.
[30] Gary S Collins,et al. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study , 2015, Statistics in medicine.
[31] Gary S Collins,et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.
[32] G. Collins,et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement , 2015, BMC medicine.
[33] Philip M. Jones,et al. Guidelines for Reporting Health Research: A User’s Manual , 2014, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.
[34] Richard Van Noorden,et al. The top 100 papers , 2014, Nature.
[35] José Villar,et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project , 2014, The Lancet.
[36] W. Sauerbrei,et al. REMARK (REporting Recommendations for Tumor MARKer Prognostic Studies) , 2014 .
[37] W. Sauerbrei,et al. STRengthening Analytical Thinking for Observational Studies: the STRATOS initiative , 2014, Statistics in medicine.
[38] Douglas G. Altman,et al. Improving the Transparency of Prognosis Research: The Role of Reporting, Data Sharing, Registration, and Protocols , 2014, PLoS medicine.
[39] Douglas G Altman,et al. The time has come to register diagnostic and prognostic research. , 2014, Clinical chemistry.
[40] G. Collins,et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting , 2014, BMC Medical Research Methodology.
[41] R. Horton,et al. How should medical science change? , 2014, The Lancet.
[42] David Moher,et al. Reducing waste from incomplete or unusable reports of biomedical research , 2014, The Lancet.
[43] P. Royston,et al. External validation of a Cox prognostic model: principles and methods , 2013, BMC Medical Research Methodology.
[44] Richard D Riley,et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research , 2013, BMJ : British Medical Journal.
[45] Richard D Riley,et al. Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes , 2013, BMJ : British Medical Journal.
[46] E. Steyerberg,et al. Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research , 2013, PLoS medicine.
[47] E. Steyerberg,et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research , 2013, PLoS medicine.
[48] Douglas G. Altman,et al. Reporting of Noninferiority and Equivalence Randomized Trials , 2013 .
[49] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.
[50] E. Steyerberg,et al. Reporting and Methods in Clinical Prediction Research: A Systematic Review , 2012, PLoS medicine.
[51] Gary S Collins,et al. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores , 2011, BMJ : British Medical Journal.
[52] D. Ransohoff,et al. Biomarker studies: a call for a comprehensive biomarker study registry , 2011, Nature Reviews Clinical Oncology.
[53] Douglas G Altman,et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. , 2010, JAMA.
[54] D. Moher,et al. Transparent and accurate reporting increases reliability, utility, and impact of your research: reporting guidelines and the EQUATOR Network , 2010, BMC medicine.
[55] Patrick Royston,et al. Reporting methods in studies developing prognostic models in cancer: a review , 2010, BMC medicine.
[56] Patrick Royston,et al. Reporting performance of prognostic models in cancer: a review , 2010, BMC medicine.
[57] D. Moher,et al. Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.
[58] W. Sauerbrei,et al. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines , 2009, British Journal of Cancer.
[59] K. Jordan,et al. Improving the quality of reporting of research studies. , 2009, Musculoskeletal care.
[60] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[61] D G Altman,et al. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.
[62] Douglas G Altman,et al. Prognostic Models: A Methodological Framework and Review of Models for Breast Cancer , 2009, Cancer investigation.
[63] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.
[64] D. Moher,et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.
[65] P. Bossuyt,et al. Reporting bias in diagnostic and prognostic studies: time for action. , 2008, Clinical chemistry.
[66] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[67] John P A Ioannidis,et al. Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.
[68] Matthias Egger,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.
[69] Richard D Riley,et al. Prognosis research: toward evidence-based results and a Cochrane methods group. , 2007, Journal of clinical epidemiology.
[70] A. Harris,et al. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.
[71] Douglas G. Altman,et al. Statistical reviewing policies of medical journals , 1998, Journal of General Internal Medicine.
[72] A. Harris,et al. Systematic Review of Multiple Studies of Prognosis: The Feasibility of Obtaining Individual Patient Data , 2007 .
[73] Richard D Riley,et al. Evidence-Based Assessment and Application of Prognostic Markers: The Long Way from Single Studies to Meta-Analysis , 2006 .
[74] Patrick Royston,et al. The cost of dichotomising continuous variables , 2006, BMJ : British Medical Journal.
[75] Douglas G Altman,et al. Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.
[76] Douglas G Altman,et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.
[77] Richard D Riley,et al. Primer: an evidence-based approach to prognostic markers , 2005, Nature Clinical Practice Oncology.
[78] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[79] W. Sauerbrei,et al. Identification of clinically useful cancer prognostic factors: what are we missing? , 2005, Journal of the National Cancer Institute.
[80] John P A Ioannidis,et al. Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.
[81] J. Ioannidis,et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.
[82] D G Altman,et al. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines , 2004, British Journal of Cancer.
[83] D. Altman,et al. CONSORT statement: extension to cluster randomised trials , 2004, BMJ : British Medical Journal.
[84] Douglas G. Altman,et al. Methodological challenges in the evaluation of prognostic factors in breast cancer , 2004, Breast Cancer Research and Treatment.
[85] Douglas G Altman,et al. Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.
[86] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.
[87] D G Altman,et al. Statistics in medical journals: some recent trends. , 2000, Statistics in medicine.
[88] F. Waldman,et al. Reproducibility of p53 Immunohistochemistry in Bladder Tumors , 2000 .
[89] D G Altman,et al. What do we mean by validating a prognostic model? , 2000, Statistics in medicine.
[90] J. Going,et al. Predicting the future: a critical appraisal of cancer prognosis studies , 1999, Histopathology.
[91] D. Altman,et al. Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.
[92] P. Royston,et al. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials , 1999 .
[93] D. Altman,et al. Statistical reviewing for medical journals. , 1998, Statistics in medicine.
[94] Douglas G. Altman,et al. Approximating statistical functions by using fractional polynomial regression , 1997 .
[95] D. Altman,et al. Statistics notes: Cronbach's alpha , 1997 .
[96] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[97] J. Wyatt,et al. Commentary: Prognostic models: clinically useful or quickly forgotten? , 1995 .
[98] D. Altman,et al. Multiple significance tests: the Bonferroni method. , 1995, BMJ.
[99] D G Altman,et al. Comparing two methods of clinical measurement: a personal history. , 1995, International journal of epidemiology.
[100] Curtis L. Meinert,et al. A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. , 1994, JAMA.
[101] P. Royston,et al. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. , 1994 .
[102] D. Altman,et al. Statistics Notes: Diagnostic tests 1: sensitivity and specificity , 1994, BMJ.
[103] R. Persaud. Correlation, regression, and repeated data , 1994, BMJ.
[104] W. Sauerbrei,et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.
[105] D. G. Altman,et al. Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.
[106] Douglas G. Altman,et al. Statistics Notes: Correlation, regression, and repeated data , 1994 .
[107] D G Altman,et al. The scandal of poor medical research , 1994, BMJ.
[108] D. Altman,et al. Charts of fetal size: 1. Methodology , 1994, British journal of obstetrics and gynaecology.
[109] D. Altman. Construction of age-related reference centiles using absolute residuals. , 1993, Statistics in medicine.
[110] Berthold Lausen,et al. Maximally selected rank statistics , 1992 .
[111] M Schumacher,et al. A bootstrap resampling procedure for model building: application to the Cox regression model. , 1992, Statistics in medicine.
[112] D G Altman,et al. Statistics in medical journals: developments in the 1980s. , 1991, Statistics in medicine.
[113] D. Altman. Categorising continuous variables. , 1991, British Journal of Cancer.
[114] Douglas G. Altman,et al. Practical statistics for medical research , 1990 .
[115] M. Fernö,et al. Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. , 1990, British Journal of Cancer.
[116] Douglas G. Altman,et al. Statistics with confidence: Confidence intervals and statistical guidelines . , 1990 .
[117] D. Altman,et al. Bootstrap investigation of the stability of a Cox regression model. , 1989, Statistics in medicine.
[118] S. Pocock,et al. Statistical problems in the reporting of clinical trials. A survey of three medical journals. , 1987, The New England journal of medicine.
[119] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[120] D. Altman,et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. , 1985, Gastroenterology.
[121] C. C. Chen,et al. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.
[122] Douglas G. Altman,et al. Measurement in Medicine: The Analysis of Method Comparison Studies , 1983 .
[123] M. Gardner,et al. Statistical guidelines for contributors to medical journals. , 1983, British medical journal.
[124] D. Siegmund,et al. Maximally Selected Chi Square Statistics , 1982 .
[125] R. Swindell,et al. Statistics in Practice , 1982, British Journal of Cancer.
[126] D G Altman,et al. Statistics in medical journals. , 1982, Statistics in medicine.
[127] D. Altman,et al. ENTERIC DISEASE IN SAN FRANCISCO , 1977, The Lancet.
[128] W. Garrard,et al. PATTERNS OF SEXUALLY TRANSMITTED ENTERIC DISEASES IN A CITY , 1977, The Lancet.
[129] B. Clarke,et al. LONG-TERM COMPARATIVE TRIAL OF GLIBENCLAMIDE AND CHLORPROPAMIDE IN DIET-FAILED, MATURITY-ONSET DIABETICS , 1975, The Lancet.
[130] Douglas G. Altman,et al. Explanation and Elaboration , 2022 .